|
|
 |
| |
|
Home > Prescription Drugs > Bisphosphonates > Bondronat: Proven Efficiency and Convenience
| |
Pharmaceutical Courses |
|
Pharmacy Technician
Allied College
Arnold, MO |
Pharmacy Technician
Allied College
Saint Ann, MO |
Pharmacy Technician
Cambridge College
Portland, OR |
Pharmacy Technician
Cambridge College
Seattle, WA |
Pharmacy Technician
High Tech Institute
Irving, TX |
Pharmacy Technician
High Tech Institute
Atlanta, GA |
Pharmacy Technician
High Tech Institute
Memphis, TN |
Pharmacy Technician
High Tech Institute
Minneapolis, MN |
Pharmacy Technician
High Tech Institute
Orlando, FL |
Pharmacy Technician
High Tech Institute
Sacramento, CA |
Pharmacy Technician
The Bryman School
Phoenix, AZ |
|
Bondronat: Proven Efficiency and Convenience
Third generation bisphosphonates include Bondronat. It decreases pain in people suffering Metastatic Bone Disease (MBD) in a fast and effective way. The European Commission for the prevention of skeletal events (bone complications that require surgery or radiotherapy and pathological fractures) recently approved the use of this drug in patients that experience bone metastases and breast cancer.
Bondronat is available intravenously and orally; a unique advantage of this drug among other bisphosphonates. The lifestyle of every patient varies, so does his/her treatment and Bondronat allows them to choose the formulation that suits their necessities better.
Some benefits of the use of the oral formulation are: convenience and the chance of being able to avoid needless and unbearable visits to hospitals. The drug can also be used by patients with serious renal injuries.
Jean-Jacques Body, a Professor from Institut Jules Bordet in Belgium is convinced of the fact that the appearance of Bondronat has a major significance in the treatment of Metastatic Bone Disease.
"In clinical trials, Bondronat has demonstrated significant improvements in quality of life for patients with MBD thanks to a marked reduction in pain associated with bone metastases. There are significantly fewer complications of MBD and the safety profile of oral and intravenous Bondronat appears to be remarkably good", said Body.
According to studies offered in the European Society of Medical Oncology (ESMO) conference, Bondronat provides major clinical benefits to patients with bone metastases from colorectal cancer. It was the first time that a study showed that Bondronat was effective in colorectal cancer patients while offering them an advantageous option of treatment for incapacitating bone metastases.
Everything you need to know about prescription medication is here at RxBoomer.com
Permission is granted to reproduce this article as long as the above resource paragraph is left intact with active links.
Permission is granted to reproduce this article as long as the above resource paragraph is left intact with active links. 2112
Back to Bisphosphonates
|
|
|
|
|
|
|
|